RPA2 [p Ser33] Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: RPA2 [p Ser33] Antibody [NB100-544]

RPA2-[p-Ser33]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-544-img0003.jpg

Western Blot: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

The effects of ARID1A on the response to replication stress and DSB induced by HU. (A and B) Western blot analysis of DDR-related genes following the exposure to 2 mM HU (A) and 4 mM HU (B) for the indicated times in ARID1A KD or OE DMS273 cells. (C to H) Cell viability (C and F) and clonal formation (D, E, G, and H) assays following 2 mM HU (C to E) and 4 mM HU (F to H) in ARID1A KD or OE DMS273 cells. n ≥ 3 independent experiments. Data are shown as the mean +/- SEM; n ≥ 3 independent experiments. Statistical analysis was performed using a one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/41049615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

ARID1A deficiency enhances JQ1 sensitivity and identifies BRD-K98645985 as a novel therapeutic candidate in SCLC. (A and B) Pearson correlation analysis of IC50 values of JQ1 from the GDSC1 dataset and the mRNA level of ARID1A (A) and MYC family gene (B). (C) Dose–response analysis of JQ1 treatment on cell viability upon ARID1A KD DMS273 and DMS53 cells. (D) Western blot analysis of DDR-related genes following the exposure to JQ1 at indicated concentrations in ARID1A KD DMS273 and DMS53 cells. (E) Tumor volume curves of DMS273 control cells (SCR) and ARID1A KD cells upon exposure to JQ1 in vivo. KD denotes shARID1A-2#. (F) Scatterplot representing tumor weights of DMS273 control cells (SCR) and ARID1A KD cells upon exposure to JQ1 at the endpoint of experiments in vivo. KD refers to shARID1A-2#. (G) Colony formation assays demonstrating the effect of BRD-K98645985 on the cytotoxicity of JQ1 in DMS273 cells. (H) Drug–response curves of BRD-K98645985 and JQ1 combination in DMS273 cells. Cells were treated with escalating doses for 72 h, with viability measured by CellTiter-Glo. (I) Bliss analysis (Combenefit software) showing synergistic effects. (J) Tumor growth curves in xenograft mice treated with JQ1, BRD-K98645985 (BRD), or their combination (JQ1 + BRD). (K) Scatterplot depicting tumor weights from xenograft mice at the endpoints of the experiments. (L) Representative images of xenograft tumors. Data are mean +/- SEM, and statistical analysis was performed using a one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (M) Proposed model depicting the function of ARID1A to modulate cell proliferation and genome stability through c-MYC and PARP1. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/41049615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

ARID1A participates in DDR in SCLC through the c-MYC/PARP axis. (A and B) Western blot analysis of DDR-related gene in DMS273 and DMS53 cells following ARID1A KD (A) or OE (B). (C and D) Representative images of immunofluorescence staining for gamma-H2AX (C) and RAD51 (D) in DMS273 and DMS53 cells following ARID1A KD. Cells with more than 5 foci were considered positive. Quantification of gamma-H2AX /RAD51 fluorescence intensities from 3 independent experiments was shown as mean +/- SD. Statistical analysis was performed using 2-tailed unpaired Student’s t tests. ****P < 0.0001. (E to G) Western blot analysis of the indicated proteins following ARID1A (E), c-MYC (F), or PARP1 (G) overexpression in ARID1A KD DMS273 and DMS53 cells. (H and I) Western blot analysis of PI3K downstream phospho-proteins in DMS273 and DMS53 cells following ARID1A KD (H) or OE (I). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/41049615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

The effects of ARID1A on the response to replication stress and DSB induced by HU. (A and B) Western blot analysis of DDR-related genes following the exposure to 2 mM HU (A) and 4 mM HU (B) for the indicated times in ARID1A KD or OE DMS273 cells. (C to H) Cell viability (C and F) and clonal formation (D, E, G, and H) assays following 2 mM HU (C to E) and 4 mM HU (F to H) in ARID1A KD or OE DMS273 cells. n ≥ 3 independent experiments. Data are shown as the mean +/- SEM; n ≥ 3 independent experiments. Statistical analysis was performed using a one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/41049615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

ARID1A participates in DDR in SCLC through the c-MYC/PARP axis. (A and B) Western blot analysis of DDR-related gene in DMS273 and DMS53 cells following ARID1A KD (A) or OE (B). (C and D) Representative images of immunofluorescence staining for gamma-H2AX (C) and RAD51 (D) in DMS273 and DMS53 cells following ARID1A KD. Cells with more than 5 foci were considered positive. Quantification of gamma-H2AX /RAD51 fluorescence intensities from 3 independent experiments was shown as mean +/- SD. Statistical analysis was performed using 2-tailed unpaired Student’s t tests. ****P < 0.0001. (E to G) Western blot analysis of the indicated proteins following ARID1A (E), c-MYC (F), or PARP1 (G) overexpression in ARID1A KD DMS273 and DMS53 cells. (H and I) Western blot analysis of PI3K downstream phospho-proteins in DMS273 and DMS53 cells following ARID1A KD (H) or OE (I). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/41049615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

Active DNA end processing in late micronuclei compartments. a: Detection and quantification of RPA32 phosphorylation (pSerine 33) and ssDNA by specific antibodies in MN compartments of OVCAR-8 cells 36 h after 2-Gy irradiation. Note the nuclear signals have reduced while those in MN were intense. n = 3 biological repeats. Error bars = s.d. **P < 0.01; ***P < 0.005 (t-test). b: Immunostaining and enumeration of phosphorylated NBS1-pSerine 343, BRCA1-pSerine 1524 and TP53-pSerine 15 in MN compartments. **P < 0.01; ***P < 0.005 (t-test). c: Representative images (Upper panel) and quantification of RPA signal in MN compartments (Lower left) or RPA foci in nuclei (lower right) of post-IR OVCAR-8 cells after indicated treatments. Pro-resection genes (MRE11, BRCA1 and WDR70) were knockdown by specific siRNA. Percentage of positive RPA32-pS33 MN population was calculated after 36 h of IR treatment Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29661159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: RPA2 [p Ser33] Antibody - BSA Free [NB100-544] -

Active DNA end processing in late micronuclei compartments. a: Detection and quantification of RPA32 phosphorylation (pSerine 33) and ssDNA by specific antibodies in MN compartments of OVCAR-8 cells 36 h after 2-Gy irradiation. Note the nuclear signals have reduced while those in MN were intense. n = 3 biological repeats. Error bars = s.d. **P < 0.01; ***P < 0.005 (t-test). b: Immunostaining and enumeration of phosphorylated NBS1-pSerine 343, BRCA1-pSerine 1524 and TP53-pSerine 15 in MN compartments. **P < 0.01; ***P < 0.005 (t-test). c: Representative images (Upper panel) and quantification of RPA signal in MN compartments (Lower left) or RPA foci in nuclei (lower right) of post-IR OVCAR-8 cells after indicated treatments. Pro-resection genes (MRE11, BRCA1 and WDR70) were knockdown by specific siRNA. Percentage of positive RPA32-pS33 MN population was calculated after 36 h of IR treatment Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29661159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.